<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2017-09-08" updated="2019-12-02">
  <drugbank-id primary="true">DB13903</drugbank-id>
  <name>Equine Botulinum Neurotoxin B Immune FAB2</name>
  <description>Equine Botulinum Neurotoxin B Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype B. It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes B in adults and pediatric patients.</description>
  <cas-number/>
  <unii>VSK09VP4HL</unii>
  <groups>
    <group>approved</group>
    <group>experimental</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Equine Botulinum Neurotoxin B Immune FAB2 is indicted for use in documented or suspected exposure to botulinum toxin serotype B in adults and pediatric patients [FDA Label].</indication>
  <pharmacodynamics>Equine Botulinum Neurotoxin B Immune FAB2 binds to botulinum toxin serotype B to prevent toxicity [FDA Label].</pharmacodynamics>
  <mechanism-of-action>Equine Botulinum Neurotoxin B Immune FAB2 is a mix of polyclonal antibodies for [DB00042] [FDA Label]. It binds to the toxin with high-affinity and prevents binding to ganglioside anchorage sites and membrane-bound receptors on cholinergic nerve terminals. This prevents internalization of the toxin into the cell and ultimately prevents it from exerting its toxic effects. Due to the long-lasting effects of botulinum toxin, the antibodies must be administered before symptoms present to prevent toxicity.</mechanism-of-action>
  <toxicity>Equine Botulinum Neurotoxin B Immune FAB2 may produce anaphylaxis or anaphylactoid reactions particularly in patients who have previously been exposed to equine-derived antivenom or antitoxins or patient with preexisting hypersensitivity to horses, asthma, or hay fever [FDA Label]. Serum sickness reactions may present 10-21 days after infusion. Various infusion reactions may occur dependent on the rate of infusion. These include chills, fever, headaches, nausea, and vomiting. Arthralgia, myalgia, and vasovagal reactions may also occur independently of infusion rate. Because the antibodies are derived from equine plasma there is a risk of infectious disease transmission although this is controlled through manufacturing processes.&#13;
</toxicity>
  <metabolism>There is no metabolism data available. Equine Botulinum Neurotoxin B Immune FAB2 is assumed to be broken down similarly to other proteins and antibodies in systemic circulation.</metabolism>
  <absorption>Administration of one vial of containing at least 3300 Units produced a mean Cmax of 1.90 Units/mL. Administration of two vials produced a mean Cmax of 4.28 Units/mL [FDA Label].</absorption>
  <half-life>Equine Botulinum Neurotoxin B Immune FAB2 was observed to have a mean half life of 34.2 h after administration of one vial and 57.1 h after two vials [FDA Label].</half-life>
  <protein-binding>There is no protein binding data available.</protein-binding>
  <route-of-elimination>No data is available on excretion of Equine Botulinum Neurotoxin B Immune FAB2.</route-of-elimination>
  <volume-of-distribution>Equine Botulinum Neurotoxin B Immune FAB2 was found to have a mean Vd of 9.607 L after administration of one vial and 14.865 L after two vials [FDA Label].</volume-of-distribution>
  <clearance>Equine Botulinum Neurotoxin B Immune FAB2 was observed to have a mean clearance rate of 196 mL/h after administration of one vial and 181 mL/h after two.</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Botulinum Neurotoxin B immune FAB2 (equine)</synonym>
    <synonym language="english" coder="">BOTULINUM NEUROTOXIN B IMMUNE FAB2, EQUINE</synonym>
  </synonyms>
  <products>
    <product>
      <name>Bat</name>
      <labeller>Emergent BioSolutions Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60492-0075</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125462</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Bat</name>
      <ingredients>Equine Botulinum Neurotoxin A Immune FAB2 + Equine Botulinum Neurotoxin B Immune FAB2 + Equine Botulinum Neurotoxin C Immune FAB2 + Equine Botulinum Neurotoxin D Immune FAB2 + Equine Botulinum Neurotoxin E Immune FAB2 + Equine Botulinum Neurotoxin F Immune FAB2 + Equine Botulinum Neurotoxin G Immune FAB2</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories/>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Liquid</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB13903.pdf?1505424712</fda-label>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <sequences/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347911472</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0001263</id>
      <name>Botulinum neurotoxin type B</name>
      <organism>Clostridium botulinum</organism>
      <actions>
        <action>antibody</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P10844" source="Swiss-Prot">
        <name>Botulinum neurotoxin type B</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Botulinum toxin acts by inhibiting neurotransmitter release. It binds to peripheral neuronal synapses, is internalized and moves by retrograde transport up the axon into the spinal cord where it can move between postsynaptic and presynaptic neurons. It inhibits neurotransmitter release by acting as a zinc endopeptidase that cleaves the '76-Gln-|-Phe-77' bond of synaptobrevin-2.</specific-function>
        <gene-name>botB</gene-name>
        <locus/>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>4.97</theoretical-pi>
        <molecular-weight>150801.16</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="1491">Clostridium botulinum</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M81186</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>144735</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P10844</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>BXB_CLOBO</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.4.24.69</synonym>
          <synonym>BoNT/B</synonym>
          <synonym>Bontoxilysin-B</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010882|Botulinum neurotoxin type B
MPVTINNFNYNDPIDNNNIIMMEPPFARGTGRYYKAFKITDRIWIIPERYTFGYKPEDFN
KSSGIFNRDVCEYYDPDYLNTNDKKNIFLQTMIKLFNRIKSKPLGEKLLEMIINGIPYLG
DRRVPLEEFNTNIASVTVNKLISNPGEVERKKGIFANLIIFGPGPVLNENETIDIGIQNH
FASREGFGGIMQMKFCPEYVSVFNNVQENKGASIFNRRGYFSDPALILMHELIHVLHGLY
GIKVDDLPIVPNEKKFFMQSTDAIQAEELYTFGGQDPSIITPSTDKSIYDKVLQNFRGIV
DRLNKVLVCISDPNININIYKNKFKDKYKFVEDSEGKYSIDVESFDKLYKSLMFGFTETN
IAENYKIKTRASYFSDSLPPVKIKNLLDNEIYTIEEGFNISDKDMEKEYRGQNKAINKQA
YEEISKEHLAVYKIQMCKSVKAPGICIDVDNEDLFFIADKNSFSDDLSKNERIEYNTQSN
YIENDFPINELILDTDLISKIELPSENTESLTDFNVDVPVYEKQPAIKKIFTDENTIFQY
LYSQTFPLDIRDISLTSSFDDALLFSNKVYSFFSMDYIKTANKVVEAGLFAGWVKQIVND
FVIEANKSNTMDKIADISLIVPYIGLALNVGNETAKGNFENAFEIAGASILLEFIPELLI
PVVGAFLLESYIDNKNKIIKTIDNALTKRNEKWSDMYGLIVAQWLSTVNTQFYTIKEGMY
KALNYQAQALEEIIKYRYNIYSEKEKSNINIDFNDINSKLNEGINQAIDNINNFINGCSV
SYLMKKMIPLAVEKLLDFDNTLKKNLLNYIDENKLYLIGSAEYEKSKVNKYLKTIMPFDL
SIYTNDTILIEMFNKYNSEILNNIILNLRYKDNNLIDLSGYGAKVEVYDGVELNDKNQFK
LTSSANSKIRVTQNQNIIFNSVFLDFSVSFWIRIPKYKNDGIQNYIHNEYTIINCMKNNS
GWKISIRGNRIIWTLIDINGKTKSVFFEYNIREDISEYINRWFFVTITNNLNNAKIYING
KLESNTDIKDIREVIANGEIIFKLDGDIDRTQFIWMKYFSIFNTELSQSNIEERYKIQSY
SEYLKDFWGNPLMYNKEYYMFNAGNKNSYIKLKKDSPVGEILTRSKYNQNSKYINYRDLY
IGEKFIIRRKSNSQSINDDIVRKEDYIYLDFFNLNQEWRVYTYKYFKKEEEKLFLAPISD
SDEFYNTIQIKEYDEQPTYSCQLLFKKDEESTDEIGLIGIHRFYESGIVFEEYKDYFCIS
KWYLKEVKRKPYNLKLGCNWQFIPKDEGWTE</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0002513|3876 bp
ATGCCAGTTACAATAAATAATTTTAATTATAATGATCCTATTGATAATAATAATATTATT
ATGATGGAGCCTCCATTTGCGAGAGGTACGGGGAGATATTATAAAGCTTTTAAAATCACA
GATCGTATTTGGATAATACCGGAAAGATATACTTTTGGATATAAACCTGAGGATTTTAAT
AAAAGTTCCGGTATTTTTAATAGAGATGTTTGTGAATATTATGATCCAGATTACTTAAAT
ACTAATGATAAAAAGAATATATTTTTACAAACAATGATCAAGTTATTTAATAGAATCAAA
TCAAAACCATTGGGTGAAAAGTTATTAGAGATGATTATAAATGGTATACCTTATCTTGGA
GATAGACGTGTTCCACTCGAAGAGTTTAACACAAACATTGCTAGTGTAACTGTTAATAAA
TTAATCAGTAATCCAGGAGAAGTGGAGCGAAAAAAAGGTATTTTCGCAAATTTAATAATA
TTTGGACCTGGGCCAGTTTTAAATGAAAATGAGACTATAGATATAGGTATACAAAATCAT
TTTGCATCAAGGGAAGGCTTCGGGGGTATAATGCAAATGAAGTTTTGCCCAGAATATGTA
AGCGTATTTAATAATGTTCAAGAAAACAAAGGCGCAAGTATATTTAATAGACGTGGATAT
TTTTCAGATCCAGCCTTGATATTAATGCATGAACTTATACATGTTTTACATGGATTATAT
GGCATTAAAGTAGATGATTTACCAATTGTACCAAATGAAAAAAAATTTTTTATGCAATCT
ACAGATGCTATACAGGCAGAAGAACTATATACATTTGGAGGACAAGATCCCAGCATCATA
ACTCCTTCTACGGATAAAAGTATCTATGATAAAGTTTTGCAAAATTTTAGAGGGATAGTT
GATAGACTTAACAAGGTTTTAGTTTGCATATCAGATCCTAACATTAATATTAATATATAT
AAAAATAAATTTAAAGATAAATATAAATTCGTTGAAGATTCTGAGGGAAAATATAGTATA
GATGTAGAAAGTTTTGATAAATTATATAAAAGCTTAATGTTTGGTTTTACAGAAACTAAT
ATAGCAGAAAATTATAAAATAAAAACTAGAGCTTCTTATTTTAGTGATTCCTTACCACCA
GTAAAAATAAAAAATTTATTAGATAATGAAATCTATACTATAGAGGAAGGGTTTAATATA
TCTGATAAAGATATGGAAAAAGAATATAGAGGTCAGAATAAAGCTATAAATAAACAAGCT
TATGAAGAAATTAGCAAGGAGCATTTGGCTGTATATAAGATACAAATGTGTAAAAGTGTT
AAAGCTCCAGGAATATGTATTGATGTTGATAATGAAGATTTGTTCTTTATAGCTGATAAA
AATAGTTTTTCAGATGATTTATCTAAAAACGAAAGAATAGAATATAATACACAGAGTAAT
TATATAGAAAATGACTTCCCTATAAATGAATTAATTTTAGATACTGATTTAATAAGTAAA
ATAGAATTACCAAGTGAAAATACAGAATCACTTACTGATTTTAATGTAGATGTTCCAGTA
TATGAAAAACAACCCGCTATAAAAAAAATTTTTACAGATGAAAATACCATCTTTCAATAT
TTATACTCTCAGACATTTCCTCTAGATATAAGAGATATAAGTTTAACATCTTCATTTGAT
GATGCATTATTATTTTCTAACAAAGTTTATTCATTTTTTTCTATGGATTATATTAAAACT
GCTAATAAAGTGGTAGAAGCAGGATTATTTGCAGGTTGGGTGAAACAGATAGTAAATGAT
TTTGTAATCGAAGCTAATAAAAGCAATACTATGGATAAAATTGCAGATATATCTCTAATT
GTTCCTTATATAGGATTAGCTTTAAATGTAGGAAATGAAACAGCTAAAGGAAATTTTGAA
AATGCTTTTGAGATTGCAGGAGCCAGTATTCTACTAGAATTTATACCAGAACTTTTAATA
CCTGTAGTTGGAGCCTTTTTATTAGAATCATATATTGACAATAAAAATAAAATTATTAAA
ACAATAGATAATGCTTTAACTAAAAGAAATGAAAAATGGAGTGATATGTACGGATTAATA
GTAGCGCAATGGCTCTCAACAGTTAATACTCAATTTTATACAATAAAAGAGGGAATGTAT
AAGGCTTTAAATTATCAAGCACAAGCATTGGAAGAAATAATAAAATACAGATATAATATA
TATTCTGAAAAAGAAAAGTCAAATATTAACATCGATTTTAATGATATAAATTCTAAACTT
AATGAGGGTATTAACCAAGCTATAGATAATATAAATAATTTTATAAATGGATGTTCTGTA
TCATATTTAATGAAAAAAATGATTCCATTAGCTGTAGAAAAATTACTAGACTTTGATAAT
ACTCTCAAAAAAAATTTGTTAAATTATATAGATGAAAATAAATTATATTTGATTGGAAGT
GCAGAATATGAAAAATCAAAAGTAAATAAATACTTGAAAACCATTATGCCGTTTGATCTT
TCAATATATACCAATGATACAATACTAATAGAAATGTTTAATAAATATAATAGCGAAATT
TTAAATAATATTATCTTAAATTTAAGATATAAGGATAATAATTTAATAGATTTATCAGGA
TATGGGGCAAAGGTAGAGGTATATGATGGAGTCGAGCTTAATGATAAAAATCAATTTAAA
TTAACTAGTTCAGCAAATAGTAAGATTAGAGTGACTCAAAATCAGAATATCATATTTAAT
AGTGTGTTCCTTGATTTTAGCGTTAGCTTTTGGATAAGAATACCTAAATATAAGAATGAT
GGTATACAAAATTATATTCATAATGAATATACAATAATTAATTGTATGAAAAATAATTCG
GGCTGGAAAATATCTATTAGGGGTAATAGGATAATATGGACTTTAATTGATATAAATGGA
AAAACCAAATCGGTATTTTTTGAATATAACATAAGAGAAGATATATCAGAGTATATAAAT
AGATGGTTTTTTGTAACTATTACTAATAATTTGAATAACGCTAAAATTTATATTAATGGT
AAGCTAGAATCAAATACAGATATTAAAGATATAAGAGAAGTTATTGCTAATGGTGAAATA
ATATTTAAATTAGATGGTGATATAGATAGAACACAATTTATTTGGATGAAATATTTCAGT
ATTTTTAATACGGAATTAAGTCAATCAAATATTGAAGAAAGATATAAAATTCAATCATAT
AGCGAATATTTAAAAGATTTTTGGGGAAATCCTTTAATGTACAATAAAGAATATTATATG
TTTAATGCGGGGAATAAAAATTCATATATTAAACTAAAGAAAGATTCACCTGTAGGTGAA
ATTTTAACACGTAGCAAATATAATCAAAATTCTAAATATATAAATTATAGAGATTTATAT
ATTGGAGAAAAATTTATTATAAGAAGAAAGTCAAATTCTCAATCTATAAATGATGATATA
GTTAGAAAAGAAGATTATATATATCTAGATTTTTTTAATTTAAATCAAGAGTGGAGAGTA
TATACCTATAAATATTTTAAGAAAGAGGAAGAAAAATTGTTTTTAGCTCCTATAAGTGAT
TCTGATGAGTTTTACAATACTATACAAATAAAAGAATATGATGAACAGCCAACATATAGT
TGTCAGTTGCTTTTTAAAAAAGATGAAGAAAGTACTGATGAGATAGGATTGATTGGTATT
CATCGTTTCTACGAATCTGGAATTGTATTTGAAGAGTATAAAGATTATTTTTGTATAAGT
AAATGGTACTTAAAAGAGGTAAAAAGGAAACCATATAATTTAAAATTGGGATGTAATTGG
CAGTTTATTCCTAAAGATGAAGGGTGGACTGAATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01742</identifier>
            <name>Peptidase_M27</name>
          </pfam>
          <pfam>
            <identifier>PF07951</identifier>
            <name>Toxin_R_bind_C</name>
          </pfam>
          <pfam>
            <identifier>PF07953</identifier>
            <name>Toxin_R_bind_N</name>
          </pfam>
          <pfam>
            <identifier>PF07952</identifier>
            <name>Toxin_trans</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>host cell cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>host cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>host cell presynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metalloendopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inhibition of neurotransmitter uptake</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pathogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>